Literature DB >> 32978674

Temozolomide showed rapid activity in a patient with refractory CNS monomorphic epitheliotropic T cell lymphoma.

Pui-Lun Yip1, Ching-Pong Lam2, Wai-Pan Lau2, Tsan-Hei Luk2, Sze-Man June Lau2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32978674     DOI： 10.1007/s00277-020-04282-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  8 in total

1.  Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group.

Authors:  Eric Tse; Harinder Gill; Florence Loong; Seok Jin Kim; Siok-Bian Ng; Tiffany Tang; Young-Hyeh Ko; Wee-Joo Chng; Soon-Thye Lim; Won Seog Kim; Yok-Lam Kwong
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

2.  Temozolomide for central nervous system involvement in mycosis fungoides.

Authors:  Thomas G Bird; Sean Whittaker; Elizabeth M Wain; Fiona Child; Stephen L Morris
Journal:  Int J Dermatol       Date:  2015-08-14       Impact factor: 2.736

3.  Monomorphic epitheliotropic intestinal T-cell lymphoma involving the central nervous system.

Authors:  Yasushi Kubota; Kana Kusaba
Journal:  Blood       Date:  2018-04-12       Impact factor: 22.113

4.  Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma.

Authors:  Marine Baron; Lisa Belin; Nathalie Cassoux; Christine Fardeau; Marion Blaizeau; Carole Soussain; Caroline Houillier; Khê Hoang-Xuan; Emmanuel Gyan; Marie-Laure Le Lez; Anne Lavaud; Pierre Soubeyran; Bahram Bodaghi; Myrto Costopoulos; Véronique Leblond; Valérie Touitou; Karim Maloum; Marie-Hélène Errera; Damien Roos-Weil; Magali Le Garff-Tavernier; Sylvain Choquet
Journal:  Blood       Date:  2020-05-14       Impact factor: 22.113

5.  Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group.

Authors:  Tamara N Shenkier; Jean-Yves Blay; Brian Patrick O'Neill; Philip Poortmans; Eckhard Thiel; Kristoph Jahnke; Lauren E Abrey; Edward Neuwelt; Richard Tsang; Tracy Batchelor; Nancy Harris; Andrés J M Ferreri; Maurilio Ponzoni; Peter O'Brien; James Rubenstein; Joseph M Connors
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

6.  Positron emission tomography computed tomography features of monomorphic epitheliotropic intestinal T-cell lymphoma.

Authors:  Thomas S Y Chan; Elaine Lee; Pek-Lan Khong; Eric W C Tse; Yok-Lam Kwong
Journal:  Hematology       Date:  2017-06-05       Impact factor: 2.269

7.  Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma.

Authors:  Jun Ho Yi; Gyeong-Won Lee; Young Rok Do; Hye Ra Jung; Jung Yong Hong; Dok Hyun Yoon; Cheolwon Suh; Yoon Seok Choi; Seong Yoon Yi; Byeong Seok Sohn; Byung-Su Kim; Sung Yong Oh; Jinny Park; Jae-Cheol Jo; Seung-Sook Lee; Young-Ha Oh; Seok Jin Kim; Won Seog Kim
Journal:  Ann Hematol       Date:  2019-09-06       Impact factor: 3.673

8.  Temozolomide as salvage treatment in primary brain lymphomas.

Authors:  M Reni; F Zaja; W Mason; J Perry; E Mazza; M Spina; R Bordonaro; F Ilariucci; M Faedi; G Corazzelli; P Manno; E Franceschi; A Pace; M Candela; A Abbadessa; C Stelitano; G Latte; A J M Ferreri
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640
  8 in total
  1 in total

1.  PEG-Asparaginase Single-Agent Rescue in an Advanced Case of Monomorphic Epitheliotropic Intestinal T Cell Lymphoma.

Authors:  Mario Luppi; Giovanna Leonardi; Emiliano Barbieri; Stefano Pozzi; Roberta Gelmini; Luca Roncati; Monica Maccaferri; Leonardo Potenza; Roberto Marasca
Journal:  J Gastrointest Cancer       Date:  2022-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.